MARKET

FOLD

FOLD

Amicus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.75
+0.15
+1.56%
After Hours: 9.75 0 0.00% 16:42 05/07 EDT
OPEN
9.67
PREV CLOSE
9.60
HIGH
9.85
LOW
9.62
VOLUME
1.81M
TURNOVER
--
52 WEEK HIGH
25.39
52 WEEK LOW
8.83
MARKET CAP
2.59B
P/E (TTM)
-9.1121
1D
5D
1M
3M
1Y
5Y
Amicus Therapeutics to Present at Upcoming Investor Conferences in May 2021
PHILADELPHIA, May 07, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences in May: Bank of Ame...
GlobeNewswire · 2d ago
Amicus Therapeutics Appoints Sebastien Martel as Senior Vice President of Strategy and Business Development
PHILADELPHIA, May 06, May 06, 2021 (GLOBE NEWSWIRE via COMTEX) -- Most Recently Served as Global Head of Rare Diseases at Sanofi Genzyme Brings Deep...
GlobeNewswire · 3d ago
Amicus Therapeutics Stock Gives Every Indication Of Being Possible Value Trap
GuruFocus News · 3d ago
Amicus Therapeutics Announces Upcoming Presentations At American Society Of Gene & Cell Therapy 24th Annual Meeting May 11
 Amicus Therapeutics (NASDAQ:FOLD), today announced the acceptance of two abstracts for presentation at the American Society of Gene & Cell Therapy 24th Annual Meeting being held virtually, May
Benzinga · 4d ago
Downtrend Call Working As Amicus Therapeut Stock Falls 53.0% (FOLD)
May 04, 2021 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified a Downtrend for Amicus Therapeut (NASDAQ:FOLD) on January 5th, 2021 at $21.90. In...
marketwatch.com · 5d ago
Amicus Therapeutics (FOLD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Zacks · 5d ago
Amicus Therapeutics Concludes Pre-BLA Meeting With FDA For AT-GAA In Pompe Disease
Benzinga · 6d ago
BRIEF-Amicus Therapeutics Announces Successful Pre-BLA Meeting With U.S. FDA For At-Gaa For The Treatment Of Pompe Disease
reuters.com · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FOLD. Analyze the recent business situations of Amicus through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FOLD stock price target is 18.14 with a high estimate of 29.00 and a low estimate of 12.50.
EPS
Institutional Holdings
Institutions: 381
Institutional Holdings: 323.91M
% Owned: 121.74%
Shares Outstanding: 266.06M
TypeInstitutionsShares
Increased
89
17.69M
New
49
10.51M
Decreased
99
24.06M
Sold Out
27
2.70M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Chairman/Chief Executive Officer/Director
John Crowley
President/Chief Operating Officer/Director
Bradley Campbell
Chief Financial Officer
Daphne Quimi
Chief Accounting Officer/Vice President - Finance/Controller
Samantha Prout
Senior Vice President
Simon Jordan
Chief Scientific Officer
Hung Do
Senior Vice President
Jill Weimer
General Counsel/Secretary
Ellen Rosenberg
Other
Jay Barth
Other
David Clark
Lead Director/Independent Director
Michael Raab
Independent Director
Lynn Bleil
Independent Director
Robert Essner
Independent Director
Michael Kelly
Independent Director
Margaret McGlynn
Independent Director
Glenn Sblendorio
Independent Director
Craig Wheeler
Independent Director
Burke Whitman
No Data
  • All
  • Financials
  • Insiders
More
About FOLD
Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The Company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.

Webull offers kinds of Amicus Therapeutics, Inc. stock information, including NASDAQ:FOLD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FOLD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FOLD stock methods without spending real money on the virtual paper trading platform.